SCHEMBL14055903

SCHEMBL14055903

C=CC(=O)N[C@H]1CCCN(S(=O)(=O)c2ccc(NC(=O)c3cc4ccccc4[nH]3)cc2)C1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 12/20 0.53
▸ F13A1 P00488 4/20 0.49
▸ TGM1 P22735 4/20 0.49
▸ TGM6 O95932 1/20 0.47
▸ RAC1 P63000 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ GHSR Q92847 2/20 0.45
▸ CDK14 O94921 1/20 0.44
▸ CCNY Q8ND76 1/20 0.44
▸ MMP2 P08253 1/20 0.44
▸ MMP14 P50281 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HCRTR1 O43613 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14056853 0.97 TGM2 (0.53) TGM2F13A1TGM1TGM6RAC1
SCHEMBL14056518 0.93 TGM2 (0.55) TGM2F13A1TGM1TGM6
SCHEMBL14057024 0.91 TGM2 (0.57) TGM2F13A1TGM1TGM6NPC1
SCHEMBL14055363 0.90 TGM2 (0.58) TGM2F13A1TGM1TGM6
SCHEMBL14057747 0.87 TGM2 (0.50) TGM2F13A1TGM1TGM6NPC1
SCHEMBL14055348 0.86 NPC1 (0.50) TGM2F13A1TGM1TGM6NPC1
SCHEMBL14056352 0.85 TGM2 (0.46) TGM2F13A1TGM1TGM6RAC1
SCHEMBL14057476 0.84 TGM2 (0.52) TGM2F13A1TGM1TGM6RAC1
SCHEMBL14057753 0.83 TGM2 (0.45) TGM2F13A1TGM1TGM6NPC1
SCHEMBL14054701 0.83 MMP2 (0.47) TGM2F13A1TGM1TGM6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889716-B2 Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof CHDI FOUNDATION, INC. (US) 2014-11-18 — — US disclosed
US-20120302539-A1 TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302539-A1 TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF HTT, TGM2, GRN TGM2 2/4885F13A1 1540/4885TGM1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback